Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study.
BACKGROUND
Multi-drug resistant tuberculosis (MDR-TB) is a major public health concern since diagnosis is often delayed, increasing the risk of spread to the community and health care workers. Treatment is prolonged, and the total cost of treating a single case is high. Diagnosis has traditionally relied upon clinical suspicion, based on risk factors and culture with sensitivity testing, a process that can take weeks or months. Rapid diagnostic molecular techniques have the potential to shorten the time to commencing appropriate therapy, but have not been put to the test under field conditions.


RESULTS
This retrospective case-control study aimed to identify risk factors for MDR-TB, and analyse the impact of testing for rifampicin resistance using RNA polymerase B (rpoB) mutations as a surrogate for MDR-TB. Forty two MDR-TB cases and 84 fully sensitive TB controls were matched by date of diagnosis; and factors including demographics, clinical presentation, microbiology findings, management and outcome were analysed using their medical records. Conventionally recognised risk factors for MDR-TB were absent in almost half (43%) of the cases, and 15% of cases were asymptomatic. A significant number of MDR-TB cases were identified in new entrants to the country. Using rpoB mutation testing, the time to diagnosis of MDR-TB was dramatically shortened by a median of 6 weeks, allowing patients to be commenced on appropriate therapy a median of 51days earlier than those diagnosed by conventional culture and sensitivity testing.


CONCLUSIONS
MDR-TB is frequently an unexpected finding, may be asymptomatic, and is particularly prevalent among TB infected new entrants to the country. Molecular resistance testing of all acid fast bacilli positive specimens has the potential to rapidly identify MDR-TB patients and commence them on appropriate therapy significantly earlier than by conventional methods.
O'Riordan
Philly
P
Department of Infection and Tropical Medicine, Lister Unit, Northwick Park Hospital, Harrow, Middlesex, United Kingdom.
Schwab
Uli
U
Logan
Sarah
S
Cooke
Graham
G
Wilkinson
Robert J
RJ
Davidson
Robert N
RN
Bassett
Paul
P
Wall
Robert
R
Pasvol
Geoffrey
G
Flanagan
Katie L
KL
D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D009154:Mutation; D012319:RNA Polymerase II / Q000235:genetics; D012189:Retrospective Studies; D012293:Rifampin / Q000494:pharmacology*; D012306:Risk; D012307:Risk Factors; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission
D000904:Antibiotics, Antitubercular; D012319:RNA Polymerase II; D012293:Rifampin
Thorax. 2006 Feb;61(2):158-63
16254056
J Clin Microbiol. 1995 Nov;33(11):2994-8
8576360
Am J Respir Crit Care Med. 2008 Apr 1;177(7):787-92
18202343
Thorax. 2000 Nov;55(11):962-3
11050268
Ann N Y Acad Sci. 2001 Dec;953:138-45
11795406
Lancet. 2007 Oct 20;370(9596):1453-7
18064739
Clin Infect Dis. 1997 Jan;24 Suppl 1:S121-30
8994791
Thorax. 2002 Feb;57(2):152-6
11828046
J Clin Microbiol. 1998 Jul;36(7):1969-73
9650946
Thorax. 2002 Sep;57(9):810-6
12200527
Lancet. 2006 Dec 16;368(9553):2142-54
17174706
Tuberculosis (Edinb). 2003;83(1-3):44-51
12758188
Emerg Infect Dis. 2006 May;12(5):752-9
16704831
Ann N Y Acad Sci. 2001 Dec;953:185-91
11795411
J Infect. 1998 Jul;37(1):39-40
9733376
Int J Tuberc Lung Dis. 2004 Aug;8(8):1012-6
15305486
J Infect. 2006 Jul;53(1):5-11
16310855
BMJ. 1993 Dec 11;307(6918):1539-40
8274925